COCH COCH
Company Profile ↓Company Overview
COCH (COCH) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $241.00K (+7.1% YoY); net profit $-23.76M.
- Trailing 12 Months Year-on-year growth — revenue +7.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.56% |
| 1 Year: | 7.11% |
Stock Price Performance
| 1 Year: | -52.17% |
| 6 Months: | +15.15% |
| 3 Months: | -1.87% |
| 1 Month: | -10.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 57.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 57.00K | 78.00K | 63.00K | 80.00K | 59.00K | 68.00K | 56.00K | 46.00K | 78.00K | 42.00K | 39.00K |
| Operating Income | -966.28K | -1.07M | -2.99M | -1.49M | -901.36K | -1.80M | -3.77M | -4.48M | -3.38M | -4.88M | -4.85M | -4.97M | -5.11M | -5.07M | -5.71M | -5.96M |
| Net Income | -1.47M | 371.14K | 5.57M | -1.87M | -1.24M | -1.34M | -13.25M | -13.34M | 1.56M | -6.27M | -3.95M | -5.96M | -5.00M | -5.69M | -6.48M | -4.35M |
| Diluted EPS | - | - | - | - | - | -0.13 | -1.31 | -1.31 | 0.13 | -0.41 | -0.29 | -0.39 | -0.29 | -0.32 | -0.35 | -0.08 |
| R&D Expense | - | - | - | - | - | 935.00K | 1.93M | 2.15M | 1.85M | 2.36M | 2.59M | 2.76M | 2.75M | 2.48M | 2.70M | 3.64M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 237.00K | 316.00K | 225.00K | 241.00K |
| Operating Income | -5.20M | -8.71M | -18.36M | -19.26M | -22.27M |
| Net Income | -251.63K | -15.92M | -29.92M | -20.80M | -23.76M |
| Diluted EPS | - | -1.57 | -2.54 | -1.49 | -1.23 |
| R&D Expense | - | 4.97M | 8.96M | 10.18M | 12.49M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 119.99K | 426.90M | 2.56M | 8.27M | 11.54M | 8.56M |
| Total Equity | 24.30K | -44.96M | -36.20M | -1.78M | -18.84M | -12.16M |
| Cash & Equivalents | 25.00K | 149.84K | 183.00K | 4.22M | - | - |
| Total Liabilities | 95.69K | 38.62M | 38.75M | 10.05M | 30.38M | 20.32M |
| Current Liabilities | 95.69K | 2.68M | 2.52M | 7.29M | 7.54M | 11.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.80M | -17.09M | -17.95M | -18.20M |
| Investing Cash Flow | - | -218.00K | -153.00K | -980.00K | -179.00K |
| Financing Cash Flow | - | 8.09M | 21.28M | 20.20M | 16.63M |
| Capital Expenditure | - | -218.00K | -153.00K | -980.00K | -179.00K |
| Free Cash Flow | - | -9.02M | -17.24M | -18.93M | -18.38M |
| Net Change in Cash | - | -931.00K | 4.04M | 1.27M | -1.75M |
| Dividends Paid | - | - | - | 2.45M | 1.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -3,673.4% | -5,809.8% | -8,558.2% | -9,240.7% |
| Net Margin % | - | -6,718.6% | -9,469.0% | -9,242.2% | -9,857.3% |
| ROE % | 0.6% | 44.0% | 1,684.8% | 110.4% | 195.4% |
| ROCE % | -1.2% | -23,529.7% | -1,862.0% | -481.4% | 741.3% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COCH
Envoy Medical shuts down its $15M stock-sale facility - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPUHA4WGFIODBELTY0c3FnOFp6ZU1POWdIcnc5MWlVRURPakdyUnRnTWxSTmdTa0ZzZHFtbTlGQ2RBcXA5cnBiaXlrcURfR3pVeURFUGRxellsZzVLQk5Kam5HYjc1NGRYeHZDWW5YbXRWZnZPaXNWTFlJRXFHNnMxRlpFSzVWSlZiQTdjby…
Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNbmNkNkt3S2hpOGNnQlptZkxmX3RBcE1NWGZ5VE1oRmlsOHB3VUR3ekZmQks3SVVvV1dDOTQ2TEhMWk1DOFczY0RRTU13QzRjNWI4LTdhX0dkSURGSUt6UkZzXzlVWVpXRV9XNUhwOG9SUV9ON1hYX2w3Z2R3NzlMbmtLZFhnVV94ZV9jUU…
COCH Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5QNkoyX2gwdTJKOFBGNVV4VWoya0dkQnY3S3VOUzZvc09JTlNXZTFHSVpIMWNzbVhya1lySmZGeDBFS1N5Sm9MczlnMEo5UmZxXzhKYmJsQlpUWVhOV0dNZkNKYnBjc0o5Sjlma1pJdW1WWlVINHFBQW9n?oc=5" target="_blank">COC…
$COCH stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOVlRDSEw1V2k5dGpabW5LUnlFeFVBRVRvYzg0dWt3UXUtZGlVVnRCUlFZcWJHN25vMEVhRzVSYThhRnlNOW9PY3hoZjhHUjlkb2NpU3ZXakZibW0yNnBuMzRPSGZiN1lqVWhoZExVODZqOWZZT3pnM1dONGFpYzJteHZJUjVMYmlWajRtUE…
COCH|Envoy Medical Inc|Price:0.700|Chg%:+0.029 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFAtdFhkMEU3TENWR3JsX1Zsekd5S3B5U3VKYUgyZU1KNGdzLXpkT3FiaXZ2RUx4d2xka2x0QlVaR2NuRWluX1loREVTWmJ1NU15LWI2dlNyVm1ZY1hnQ3AzU1RfaGpJVWg5TDZYdUJB?oc=5" target="_blank">COCH|Envoy Medical …
Envoy Medical Reports Full Year 2025 Financial Results - TMX Newsfile
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOdGx1d3U0RElMd2Rub21HWDRSWFpwOW9uejdVZzU1MEZUM2VLbnZNemc2MzJYaTBxV3ZWVkptbnJGdlBaU091cS0tWk1qTUo2bmFuOUx5dm4xZm9DN2lUamRZRFU4WUhmTFZDcDV4eU5sRW0yQmF2X0xXZkFPaUt4aFQ4VUFNOWs1MzdkRX…
COCH — Frequently Asked Questions
What is the current share price of COCH?
As of 2026-08-05 17:25 PDT, COCH trades at $0.68 on NASDAQ/NYSE. Its 52-week range is $0.39 to $1.59.
What is the P/E ratio of COCH?
COCH trades at a trailing price-to-earnings (P/E) ratio of -0.55.
Is COCH a good stock to buy?
This page provides a data-driven analysis of COCH, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.